Jump to content

PubMed RSS Feed - - Non-Obligatory Role of Prostaglandin D2 Receptor Subtype 1 in Rosacea: Laropripant in Comparison to a Placebo Did Not Alleviate th


rss

Recommended Posts

Non-Obligatory Role of Prostaglandin D2 Receptor Subtype 1 in Rosacea: Laropripant in Comparison to a Placebo Did Not Alleviate the symptoms of Erythematoelangiectaic Rosacea.

J Clin Pharmacol. 2014 Aug 20;

Authors: Krishna R, Guo Y, Schulz V, Cord-Cruz E, Smith S, Hair S, Nahm WK, Draelos ZD

Abstract
Erythematotelangiectatic rosacea shares facial flushing features with those seen after niacin. This study was performed to test the hypothesis whether prostaglandin D2 (PGD2) receptor subtype 1 antagonist (MK-0524) will improve the symptoms of rosacea. The purpose of this study was to evaluate the effect of MK-0524 100 mg administered once daily for 4 weeks on the signs and symptoms of erythematotelangiectatic rosacea. Subjects received MK-0524 100 mg once-daily (n = 30) or placebo (n = 30) for 4 weeks. The primary pharmacodynamics endpoint was change in Clinician's Erythema Assessment (CEA) score from Baseline to Week 4. The Patient Self-Assessment (PSA) was a secondary endpoint. MK-0524 was generally well tolerated in this study For the primary endpoint of change in CEA score from Baseline to Week 4, the least-squares mean of change from Baseline to Visit 4/Week 4 was -3.7 and -3.4 for placebo and MK 0524 (100 mg), respectively. The least-squares mean difference (placebo minus MK-0524) with 90% confidence interval of change in CEA score from Baseline to Visit 4/Week 4 was estimated as -0.3 (-1.6, 1.0). For the secondary endpoints, the least-squares mean difference (placebo minus MK-0524) with 90% confidence interval of change from Baseline to Visit 4/Week 4 was estimated as -0.7 (-7.7, 6.4) for PSA total score, -4.5 (-14.2, 5.3) for PSA emotion score, -1.3 (-7.8, 5.3) for PSA symptoms score, and 3.6 (-4.3, 11.4) for PSA functioning score. MK-0524 administered once daily for 4 weeks was generally well tolerated in this population of subjects with rosacea. However, there were no clinically meaningful changes in the primary endpoint of CEA given that the response to MK-0524 could not be differentiated from that to placebo. There was also no clinically meaningful change in the secondary endpoint, PSA. A DP1 antagonist is not likely to be effective in rosacea.

PMID: 25142778 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25142778?dopt=Abstract = URL to article

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...